These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 26938948)

  • 1. Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
    Nayar N; Briscoe K; Fernandez Penas P
    J Immunother; 2016 Apr; 39(3):149-52. PubMed ID: 26938948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review.
    Logan IT; Zaman S; Hussein L; Perrett CM
    J Immunother; 2020 Apr; 43(3):89-92. PubMed ID: 31651559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.
    Vivar KL; Deschaine M; Messina J; Divine JM; Rabionet A; Patel N; Harrington MA; Seminario-Vidal L
    J Cutan Pathol; 2017 Apr; 44(4):381-384. PubMed ID: 28000240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab (OPDIVOO) BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage.
    Prescrire Int; 2016 Dec; 25(177):289-292. PubMed ID: 30758924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/ Ipilimumab Combination Therapy in Metastatic Melanoma.
    Lee O; Masood M; Nutan F
    J Drugs Dermatol; 2022 May; 21(5):529-530. PubMed ID: 35533039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
    Weber J; Gibney G; Kudchadkar R; Yu B; Cheng P; Martinez AJ; Kroeger J; Richards A; McCormick L; Moberg V; Cronin H; Zhao X; Schell M; Chen YA
    Cancer Immunol Res; 2016 Apr; 4(4):345-53. PubMed ID: 26873574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure.
    Arenbergerova M; Mrazova I; Horazdovsky J; Sticova E; Fialova A; Arenberger P
    J Eur Acad Dermatol Venereol; 2017 May; 31(5):e253-e254. PubMed ID: 27739125
    [No Abstract]   [Full Text] [Related]  

  • 9. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
    Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
    Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vemurafenib-induced toxic epidermal necrolysis].
    Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
    Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.
    Pintova S; Sidhu H; Friedlander PA; Holcombe RF
    Melanoma Res; 2013 Dec; 23(6):498-501. PubMed ID: 24113862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
    Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
    Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic epidermal necrolysis associated with pembrolizumab.
    Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab in previously untreated melanoma without BRAF mutation.
    Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
    N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.
    Tanaka R; Maruyama H; Tomidokoro Y; Yanagiha K; Hirabayashi T; Ishii A; Okune M; Inoue S; Sekine I; Tamaoka A; Fujimoto M
    Jpn J Clin Oncol; 2016 Sep; 46(9):875-8. PubMed ID: 27380808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
    Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
    Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab: Immunotherapy in Malignant Melanoma.
    Bayless H; Schneider S
    Clin J Oncol Nurs; 2015 Aug; 19(4):430-2. PubMed ID: 26207707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma: efficacy and tolerability in an elderly patient.
    Sponghini A; Patrucco F; Giorgione R; Farinelli P; Zottarelli F; Rondonotti D; Savoia P
    Anticancer Drugs; 2017 Aug; 28(7):808-810. PubMed ID: 28489616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
    Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
    Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.